You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for UBP1112
UBP1112 is an a selective group III mGlu receptor antagonist (apparent Kd values are 5.1 and 488 μM for group III and group II mGlu receptors respectively; IC50 > 1 mM for group I, NMDA, AMPA and kainate receptors).
Technical Data for UBP1112
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for UBP1112
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for UBP1112
The following data is based on the product molecular weight 259.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.86 mL||19.29 mL||38.58 mL|
|5 mM||0.77 mL||3.86 mL||7.72 mL|
|10 mM||0.39 mL||1.93 mL||3.86 mL|
|50 mM||0.08 mL||0.39 mL||0.77 mL|
References for UBP1112
References are publications that support the biological activity of the product.
Conway et al (2001) Synthesis of phenylglycine derivatives as potent and selective antagonists of group III metabotropic glutamate receptors. Bioorg.Med.Chem.Lett. 11 777 PMID: 11277518
Miller et al (2003) Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals. Br.J.Pharmacol. 139 1523 PMID: 12922940
If you know of a relevant reference for UBP1112, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: UBP1112, UBP1112 supplier, Group, III, antagonists, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGlu4R, mGlu6R, mGlu7R, mGlu8R, Glutamate, Metabotropic, UBP, 1112, (Metabotropic), 1369, Tocris Bioscience
2 Citations for UBP1112
Citations are publications that use Tocris products. Selected citations for UBP1112 include:
Govea et al (2012) Group III metabotropic glutamate receptors and transient receptor potential vanilloid 1 co-localize and interact on nociceptors. J Biol Chem 217 130 PMID: 22609935
Proudfoot et al (2006) Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 16 1591 PMID: 16920620
Do you know of a great paper that uses UBP1112 from Tocris? Please let us know.
Reviews for UBP1112
There are currently no reviews for this product. Be the first to review UBP1112 and earn rewards!
Have you used UBP1112?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.